Significant tumour growth inhibition was achieved when combining intratumoural telratolimod with systemic agonistic anti-OX40 compared to either agent given alone, which may be due to observed increases in OX40 receptor expression in treated tumours as a result of TLR7/8 agonism [29]. This evidence concerns the gene TNFRSF4 and neoplasm.